Stocks
BioCardia, Inc.BCDA
NASDAQHealthcareBiotechnology$0.92
Price as of · delayed, not real-time
A developer of cellular therapies for cardiovascular diseases, BioCardia focuses on autologous and allogeneic cell-based treatments delivered via its proprietary catheter system. The company's lead program targets chronic myocardial ischemia and heart failure, with a pipeline that also includes an investigational COVID-19 therapy. Investors track BioCardia for its early-stage clinical progress and its position in the regenerative medicine space.
52W Range: $0.75-$1.80
Congressional Interest in BioCardia, Inc. (BCDA)
No congressional trades have been disclosed for BioCardia, Inc. (BCDA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading BCDA?
No congressional trades found for this stock.